Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma
暂无分享,去创建一个
Mithat Gönen | Mari Mino-Kenudson | Olca Basturk | Peter J. Allen | Deborah Kuk | Jin He | Christopher L. Wolfgang | John L. Cameron | Ralph H. Hruban | K. Lillemoe | J. Cameron | R. Hruban | M. Gönen | M. Mino‐Kenudson | O. Basturk | D. Klimstra | elliot k fishman | P. Allen | Jin He | M. Weiss | D. Kuk | C. Ferrone | David S. Klimstra | Cristina R. Ferrone | Keith D. Lillemoe | C. F. Castillo | Vicente Morales-Oyarvide | Carlos Fernandez-del Castillo | Matthew J. Weiss | V. Morales-Oyarvide | M. Weiss
[1] D. Gouma,et al. Question Sets and Answers , 2014, Surgery.
[2] Sudeshna,et al. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: , 2022 .
[3] G. Wilding,et al. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. , 2012, Journal of gastrointestinal oncology.
[4] T. Keck,et al. The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer , 2009, Journal of Gastrointestinal Surgery.
[5] H. Ohge,et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. , 2010, Journal of the American College of Surgeons.
[6] F. Harrell,et al. Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.
[7] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[8] T. Therneau,et al. Number of Lymph Nodes Evaluated: Prognostic Value in Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.
[9] Olca Basturk,et al. Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. , 2012, Seminars in diagnostic pathology.
[10] R. Abrams,et al. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. , 2012, International journal of radiation oncology, biology, physics.
[11] M. Gönen,et al. Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer , 2007, Journal of Gastrointestinal Surgery.
[12] Laura H. Tang,et al. Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades , 2011, Annals of Surgical Oncology.
[13] A. Krasinskas,et al. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging , 2015, Annals of Surgical Oncology.
[14] K. Lillemoe,et al. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (⩽20-mm Invasive Component): A Multi-institutional Analysis , 2016, Annals of surgery.
[15] T. Meyer,et al. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[16] M. Büchler,et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. , 2015, Annals of surgery.